Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
Authors
Changqing Xie
Thoracic and GI Oncology Branch, CCR, NCI, NIH, Bethesda, MD;
Changqing Xie , M. Cecilia Monge B. , Donna Mabry-Hrones , Kelley Lauren Coffman , Stephanie Hicks , Bernadette Redd , Brad Wood , Steven Highfill , Mitchell Ho , Tim F. Greten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05003895
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS624)
DOI
10.1200/JCO.2023.41.4_suppl.TPS624
Abstract #
TPS624
Poster Bd #
N13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
First Author: Bo Zhai
Poster
2022 ASCO Annual Meeting
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Loretta J. Nastoupil
Poster
2021 ASCO Annual Meeting
Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.
First Author: Weijia Fang
Poster
2019 Genitourinary Cancers Symposium
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
First Author: Vivek Narayan